Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Glucose Monitoring Methods May Not Work Well with Some Medical Products
The U.S. Food and Drug Administration (FDA) is advising health care providers that their patients should not use certain glucose monitoring methods if they are also receiving therapeutic products containing non-glucose sugars, such as peritoneal dialysis solutions and certain immunoglobulins. The glucose test strips causing concern are those containing glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ), including certain AccuCheck test strips, manufactured by Roche Diagnostics, and some Freestyle brand test strips, manufactured by Abbott Diabetes Care. These products can falsely elevate glucose results, which may prompt patients to use or to be administered too much insulin. These therapeutic products, which are labeled to indicate that they may interfere with this particular glucose monitoring technology, are mostly used in patients with serious medical conditions, including kidney failure and moderate to severe rheumatoid arthritis. The affected products are listed at http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm176992.htm#attachment.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
Summary Judgment Denied Defendant in Declaratory Action by Producer of To Kill a Mockingbird Broadway Play Seeking Amateur Theatrical Rights
“Baseball arbitration” refers to the process used in Major League Baseball in which if an eligible player's representative and the club ownership cannot reach a compensation agreement through negotiation, each party enters a final submission and during a formal hearing each side — player and management — presents its case and then the designated panel of arbitrators chooses one of the salary bids with no other result being allowed. This method has become increasingly popular even beyond the sport of baseball.
Executives have access to some of the company's most sensitive information, and they're increasingly being targeted by hackers looking to steal company secrets or to perpetrate cybercrimes.
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?